BioPharmaSpec announced it is expanding its in-house capabilities for characterizing higher order protein structure. The new in-house services allow clients access to an increased range of BioPharmaSpec’s flexible, expert characterization methods to accurately and cost-effectively define Critical Quality Attributes of their biopharmaceuticals.
With the addition of new scientific expertise to the BioPharmaSpec leadership team and further investment in equipment in the US Laboratory, BioPharmaSpec has expanded its in-house services to include: Circular Dichroism, Fourier Transform Infrared Spectroscopy, and Intrinsic Fluorescence. These capabilities allow secondary and tertiary structure analysis comparisons alongside BioPharmaSpec’s primary structure characterization services, providing clients with reliable data that fulfill regulatory requirements.
“Expanding our in-house capabilities to assess higher order protein structure provides Clients with access to a full range of analytical expertise and means we can assist in planning comprehensive, regulatory compliant characterization strategies,” Dr. Mark Millichip, Technical Director at BioPharmaSpec said. “This will support formulation and process development, as well as biosimilar comparability and stability studies, thus helping our Clients to reduce development timelines of their biopharmaceuticals.”
“We are delighted to be investing in expanding our in-house analytical services because this means new and existing scientific clients have the unique opportunity of accessing comprehensive technical expertise in both the USA and the UK together with the speed and flexibility that partnering with a more specialized CRO provides,” Chris Ziegenfuss, Laboratory Manager said.